A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants

This phase 1, randomized, double-blind, placebo-controlled study of aficamten (formerly CK-3773274) in healthy adults identified a pharmacologically active range of doses and exposures. At doses that were pharmacologically active (single doses of ≤50 mg or daily dosing of ≤10 mg for 14 or 17 days),...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Fady I., Robertson, Laura A., Armas, Danielle R., Robbie, Edward P., Osmukhina, Anna, Xu, Donghong, Li, Hanbin, Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research - Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436819/
https://www.ncbi.nlm.nih.gov/pubmed/36061336
http://dx.doi.org/10.1016/j.jacbts.2022.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436819/
https://www.ncbi.nlm.nih.gov/pubmed/36061336
http://dx.doi.org/10.1016/j.jacbts.2022.04.008

Ejemplares similares